Business
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
In a statement to the New York Times, Bright said he has pushed for science, not politics, as the key to battling the pandemic.
A new life sciences facility dubbed The Labs has opened in Chicago providing necessary wet lab space for companies looking to expand their physical presence in the Windy City and cement the city’s reputation as a hub for cutting edge biomedical innovation.
Ken Pienta, acting chief medical officer of Cue Biopharma, said the researchers believe that CUE-101 may lead to enhanced anti-tumor activity in combination with Merck’s powerhouse checkpoint inhibitor.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.
After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.
The collaboration for development and commercialization combines Esperion’s knowledge in lipid management and Otsuka’s extensive cardiovascular drug advancement and marketing in Japan.